| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 4,791,000 | 4,146,000 | 3,768,000 | 3,765,000 | 3,412,000 |
| Sales Growth | +15.56% | +10.03% | +0.08% | +10.35% | unch |
| Net Income | -317,000 | -260,000 | 6,000 | 182,000 | -18,000 |
| Net Income Growth | -21.92% | -4,433.33% | -96.70% | +1,111.11% | unch |
Bausch & Lomb Corp (BLCO)
13.88 x 100 14.15 x 3,500
Post-market by (Cboe BZX)
14.13 -0.87 (-5.80%) 03/28/25 [NYSE]
13.88 x 100 14.15 x 3,500
Post-market 14.15 +0.02 (+0.14%) 19:57 ET
for Fri, Mar 28th, 2025
Bausch Lomb Corporation is an eye health company. Its product portfolio includes Biotrue(R) and renu(R) multi-purpose solutions, Biotrue(R) ONEday daily disposable contact lenses, LUMIFY(R) redness reliever eye drops, PreserVision(R) AREDS 2 formula eye vitamin and mineral supplements and VYZULTA(R). Bausch Lomb Corporation is based in VAUGHAN, ON.
Fiscal Year End Date: 12/31